Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The type I insulin-like growth factor receptor (IGF1R) and Src pathways are implicated in cancer development and progression.
• Src activation leads to resistance against anti-IGF1R therapies, posing a challenge for current cancer treatments.
• Concurrent targeting of IGF1R and Src is a therapeutic goal, but potential toxicity necessitates novel strategies.

Purpose of the Study:

• To synthesize and evaluate novel 4-aminopyrazolo[3,4-d]pyrimidine-based compounds as dual IGF1R/Src inhibitors.
• To assess the antitumor potential of the lead compound, LL28, in vitro and in vivo.
• To investigate LL28's efficacy in non-small cell lung cancer (NSCLC) models, including a Kras-driven spontaneous lung tumorigenesis model.

Main Methods:

• Synthesis of 4-aminopyrazolo[3,4-d]pyrimidine derivatives.
• In vitro evaluation using MTT and colony formation assays.
• Apoptosis induction assessed by flow cytometry.
• In vivo studies using NSCLC xenograft and Kras ^G12D/+ -driven lung tumorigenesis mouse models.

Main Results:

• LL28 significantly inhibited IGF1R and Src activation in NSCLC cell lines.
• LL28 induced apoptosis and suppressed cancer cell viability in vitro.
• LL28 demonstrated significant tumor growth suppression in xenograft models without overt toxicity.
• LL28 reduced lung tumor multiplicity, volume, and tumor load in the Kras ^G12D/+ model.

Conclusions:

• LL28 is a potent dual inhibitor of IGF1R and Src with promising preclinical antitumor activity.
• LL28 represents a potential novel therapeutic candidate for cancers resistant to current therapies.
• Further preclinical and clinical investigations are warranted to establish LL28's therapeutic utility.